Past and future of the mitotic spindle as an oncology target

Curr Opin Pharmacol. 2001 Aug;1(4):370-7. doi: 10.1016/s1471-4892(01)00064-9.

Abstract

Tubulin poisons were first discovered decades ago, but the recent clinical and commercial success of Taxol has led to a renaissance in the search for novel mitotic spindle poisons to treat cancer. Many tubulin poisons have been identified, but few have demonstrated clinical utility. Recent studies have begun to identify the factors that differentiate the efficacy of these agents. In addition, promising alternative approaches to targeting the mitotic spindle have been identified from detailed studies of mitotic regulation and mechanics.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Kinesin / antagonists & inhibitors
  • Kinesin / pharmacology
  • Neoplasms / drug therapy*
  • Neoplasms / pathology*
  • Spindle Apparatus / drug effects*
  • Tubulin / drug effects

Substances

  • Antineoplastic Agents
  • Tubulin
  • Kinesin